Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How does cell-based non-invasive prenatal test (NIPT) perform against chorionic villus sampling and cell-free NIPT in detecting trisomies and copy number variations? A clinical study from Denmark.
Hatt L, Ravn K, Dahl Jeppesen L, Hestbek Nicolaisen B, Baasch Christensen I, Singh R, Schelde P, Horsholt Thomsen S, Christensen R, Sinding M, Vase L, Oestergaard M, Bender Ruggard M, Jensen HS, Mogensen H, Uldbjerg N, Becher N, Markholt S, Sandager P, Henning Pedersen L, Vogel I. Hatt L, et al. Among authors: oestergaard m. Prenat Diagn. 2023 Jun;43(7):854-864. doi: 10.1002/pd.6387. Epub 2023 May 25. Prenat Diagn. 2023. PMID: 37199490
Global myocardial oedema in resuscitated out-of-hospital cardiac arrest patients assessed by cardiac magnetic resonance: a pilot study.
Klein A, Grand J, Meyer MAS, Wiberg S, Mogelvang R, Vejlstrup N, Schousboe B, Gjedsted J, Oestergaard M, Wanscher M, Kjaergaard J, Hassager C. Klein A, et al. Among authors: oestergaard m. Eur Heart J Acute Cardiovasc Care. 2023 Jan 27;12(1):53-57. doi: 10.1093/ehjacc/zuac159. Eur Heart J Acute Cardiovasc Care. 2023. PMID: 36567498
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trneny M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg MS. Nowicka M, et al. Among authors: oestergaard mz. Blood Adv. 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770. Blood Adv. 2021. PMID: 34323958 Free PMC article.
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trněný M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Strefford JC, et al. Among authors: oestergaard mz. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985. Blood Adv. 2021. PMID: 34323957 Free PMC article.
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. Kostakoglu L, et al. Among authors: oestergaard mz. Blood Adv. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690. Blood Adv. 2021. PMID: 33651099 Free PMC article. Clinical Trial.
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
Szafer-Glusman E, Liu J, Sinha A, Peale FV Jr, Ray J, Horn C, Oestergaard MZ, Kornacker M, Sehn LH, Vitolo U, Knapp A, Venstrom J, Byrtek M, Punnoose E. Szafer-Glusman E, et al. Among authors: oestergaard mz. Leuk Lymphoma. 2021 Apr;62(4):999-1002. doi: 10.1080/10428194.2020.1849674. Epub 2020 Dec 16. Leuk Lymphoma. 2021. PMID: 33325309 No abstract available.
38 results